 Home > Medical News > Latest Medical News > Pfizer 20-valent Pneumococcal Conjugate Vaccine Phase 3 Clinical Results Positive

Pfizer 20-valent Pneumococcal Conjugate Vaccine Phase 3 Clinical Results Positive

 Last Update: 2021-10-22
 Source: Internet
 Author: User

Tags

3 4 water

study mushrooms

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 29, 2021, Pfizer announced that a phase 3 clinical trial of the 20-valent pneumococcal conjugate vaccine Prevnar 20 has achieved positive top-line results

A total of 1796 subjects were enrolled in this trial, and 1727 subjects completed the trial

Prevnar 20 is Pfizer's next-generation pneumococcal conjugate vaccine, containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14) included in Prevnar 13 (13-valent pneumococcal conjugate vaccine) , 18C, 19A, 19F, and 23F) capsular polysaccharide conjugates, and also contain the capsular polysaccharide conjugates of the other 7 serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) that cause invasive pneumococcal disease They are associated with high mortality, antibiotic resistance, and/or meningitis

Reference materials:

[1] Positive Top-Line Results Of Pfizer'S Phase 3 Study Exploring Coadministration Of Prevnar 20™ With Seasonal Flu Vaccine In Older Adults Released.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express delivery and influenza vaccination at the same time, Pfizer 20-valent pneumococcal conjugate vaccine Phase 3 clinical results are positive

10-10

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Pfizer 20-valent Pneumococcal Conjugate Vaccine Phase 3 Clinical Results Positive

Related Articles

Express delivery and influenza vaccination at the same time, Pfizer 20-valent pneumococcal conjugate vaccine Phase 3 clinical results are positive